{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28275"}]}],"title":"Negative (<35 U/mL)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"400"}]}],"title":"Positive (>= 35 U/mL)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"58"}]}],"title":"Inadequate screen"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28733"}],"units":"Participants"}],"description":"Cancer Antigen 125 (CA-125) result.","groups":[{"description":"Participants undergo blood sample collection for CA-125 analysis at baseline annually for 5 years. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years.","id":"OG000","title":"Ovarian Screening"}],"paramType":"NUMBER","populationDescription":"Females in the Ovarian Screening arm (excluding females with no ovaries at baseline) who had a CA-125 screen at T0 were analyzed.","reportingStatus":"POSTED","timeFrame":"T0 (at study entry)","title":"T0 (Baseline) CA-125 Screening Results","type":"SECONDARY","unitOfMeasure":"Participants"}